Adaptive Biotechnologies Announces clonoSEQ Research Presentations for ASH 2026
Adaptive Biotechnologies announced that its clonoSEQ test for measurable residual disease (MRD) will be featured in approximately 100 abstracts at the 68th Annual Meeting of the American Society of Hematology (ASH).